Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
By F. Holz, R. Tadayoni, S. Beatty, A. Berger, M. Cereda, R. Cortez, Carel B. Hoyng, P. Hykin, G. Staurenghi, S. Heldner and 3 more. British Journal of Ophthalmology, 2014
601 citations recorded by the source corpus.
Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela. Methods Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011. Results 2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity. Conclusions In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time. Trial registration number NCT01447043.
Subfields: Epidemiology, Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/afacf4c1d21e85ab881fef7a2aa881acb978f68a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Pharmacokinetic aspects of retinal drug delivery. (2017, neutral): “These injections should be given every month or two months, but in practice the compliance is poor and the injections are given at longer intervals (Cohen et al., 2013; Holz et al., 2015).”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “A recent multi-country, retrospective study of 2,227 patients with neovascular AMD indicated that, in actual clinical usage, patients receive fewer injections and have poorer outcomes than is observed in clinical studies 234 .”
- VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “In real-life clinical settings, it has been demonstrated that patients receive fewer anti-VEGF injections than in clinical trials, and it has been suggested that this may correlate with poor visual outcomes due, at least in part, to insufficient anti-VEGF treatment (Holz et al., 2015).”